Research analysts at StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the stock.
ObsEva Stock Up 45.5 %
OBSV opened at $0.08 on Friday. The stock has a market cap of $6.24 million, a PE ratio of -0.09 and a beta of 0.68. The business has a 50 day moving average of $0.06 and a 200-day moving average of $0.07. ObsEva has a 52 week low of $0.08 and a 52 week high of $2.14.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in OBSV. Bank of America Corp DE raised its stake in ObsEva by 54,142.2% during the first quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock valued at $731,000 after buying an additional 483,490 shares during the last quarter. Two Sigma Investments LP purchased a new position in ObsEva during the third quarter valued at $25,000. Credit Suisse AG raised its stake in ObsEva by 11.0% during the fourth quarter. Credit Suisse AG now owns 1,750,573 shares of the company’s stock valued at $255,000 after buying an additional 173,455 shares during the last quarter. Millennium Management LLC purchased a new position in ObsEva during the second quarter valued at $192,000. Finally, XTX Topco Ltd raised its stake in ObsEva by 33.9% during the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after buying an additional 20,196 shares during the last quarter. Hedge funds and other institutional investors own 17.52% of the company’s stock.
ObsEva Company Profile
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Featured Articles
- Five stocks we like better than ObsEva
- How and Why to Invest in Oil Stocks
- Shocking uranium play that hedge funds kept hidden
- Investing in Agriculture 101: How to Invest in Agriculture
- Dependable dividends: Why utility stocks are on fire
- Why is the Ex-Dividend Date Significant to Investors?
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.
